Cingulate to Participate in the Healthcare Virtual Conference Part II Presented by Maxim Group and Hosted by M-Vest
June 14, 2023 15:45 ET
|
Cingulate Inc.
KANSAS CITY, Kan., June 14, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate Completes Phase 3 Adult Trial of CTx-1301 (dexmethylphenidate) for ADHD
June 08, 2023 07:00 ET
|
Cingulate Inc.
Study Assessed Onset and Duration of CTx-1301 in Adults, Results Expected 3Q 2023 Pivotal Phase 3 Trials in Pediatric/Adolescent Patients on Schedule for 3Q 2023 Initiation KANSAS CITY, Kan., June ...
Global Drug Delivery Partnering Deal Terms and Agreements Analysis Report 2023: Review Drug Delivery Deal Trends, Key Players, & Top Deal Values for Deals Signed Since 2016
June 06, 2023 03:13 ET
|
Research and Markets
Dublin, June 06, 2023 (GLOBE NEWSWIRE) -- The "Global Drug Delivery Partnering Terms and Agreements 2016-2023" report has been added to ResearchAndMarkets.com's offering.The Global Drug delivery...
Cingulate, Indegene to Participate in Benzinga All Live Access Event
May 12, 2023 15:45 ET
|
Cingulate Inc.
KANSAS CITY, Kan., May 12, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate Completes First Cohort of Phase 3 Adult Onset and Duration Trial of CTx-1301 (dexmethylphenidate) for ADHD
April 04, 2023 06:45 ET
|
Cingulate Inc.
Trial On Track for 3Q 2023 Results Pivotal Phase 3 Trial in Pediatric/Adolescent Patients Planned to Begin Mid-2023 KANSAS CITY, Kan., April 04, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:...
Cingulate Announces Positive Top-Line Results from Fed/Fast Study of Lead Asset CTx-1301 for ADHD
February 23, 2023 16:30 ET
|
Cingulate Inc.
Primary Endpoints Demonstrate CTx-1301 Can be Taken With or Without Food CTx-1301 is Designed as a True, Entire Active-Day Treatment for ADHD KANSAS CITY, Kan., Feb. 23, 2023 (GLOBE NEWSWIRE) --...
Long-Acting Drug Delivery Technologies and Services Global Market Report 2023: Continued Shift from Conventional Drug Delivery Strategies Boosts Growth
January 31, 2023 07:58 ET
|
Research and Markets
Dublin, Jan. 31, 2023 (GLOBE NEWSWIRE) -- The "Long-Acting Drug Delivery Technologies and Services Market - Distribution by Principle, Strategy, Compatible Dosage Form, Type of Molecule Delivered,...
Non-Viral / Intracellular Drug Delivery Systems Global Market Report 2022: Demand for Systems That Can Efficiently Deliver Therapeutic Interventions in Intracellular Spaces Bolsters Growth
January 13, 2023 07:28 ET
|
Research and Markets
Dublin, Jan. 13, 2023 (GLOBE NEWSWIRE) -- The "Non-Viral / Intracellular Drug Delivery Systems Market by Type of Molecule, Type of Biologics Delivered, Type of Vehicle Used, Type of Therapeutic...
Global Controlled Release Drug Delivery Market Analysis Report 2022-2028: Comprehensive Clinical insight on 200+ Drugs in Clinical Trials and 150+ Drug Available in the Market
January 09, 2023 07:33 ET
|
Research and Markets
Dublin, Jan. 09, 2023 (GLOBE NEWSWIRE) -- The "Global Controlled Release Drug Delivery Market, Drug Dosage, Price and Clinical Trial Insight 2028" clinical trials has been added to ...
Cingulate Initiates Phase 3 Study of Lead Asset CTx-1301, Designed as a True Entire Active-Day Treatment for ADHD
January 04, 2023 06:45 ET
|
Cingulate Inc.
Trial Results Expected 1H 2023 Company to Host Investor and Business Development Meetings Adjacent to Upcoming J.P. Morgan Healthcare Conference in San Francisco KANSAS CITY, Kan., Jan. 04,...